HomeCompareBIOC vs ADC

BIOC vs ADC: Dividend Comparison 2026

BIOC yields 459.88% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BIOC wins by $32353.01M in total portfolio value
10 years
BIOC
BIOC
● Live price
459.88%
Share price
$0.43
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32353.19M
Annual income
$22,660,147,667.77
Full BIOC calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — BIOC vs ADC

📍 BIOC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBIOCADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BIOC + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BIOC pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BIOC
Annual income on $10K today (after 15% tax)
$39,089.45/yr
After 10yr DRIP, annual income (after tax)
$19,261,125,517.60/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, BIOC beats the other by $19,261,056,839.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BIOC + ADC for your $10,000?

BIOC: 50%ADC: 50%
100% ADC50/50100% BIOC
Portfolio after 10yr
$16176.68M
Annual income
$11,330,114,232.54/yr
Blended yield
70.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

BIOC
Analyst Ratings
1
Buy
2
Hold
Consensus: Hold
Altman Z
-24.7
Piotroski
3/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BIOC buys
0
ADC buys
0
No recent congressional trades found for BIOC or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBIOCADC
Forward yield459.88%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$32353.19M$178.9K
Annual income after 10y$22,660,147,667.77$80,797.29
Total dividends collected$31493.31M$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusHoldBuy

Year-by-year: BIOC vs ADC ($10,000, DRIP)

YearBIOC PortfolioBIOC Income/yrADC PortfolioADC Income/yrGap
1← crossover$56,688$45,987.58$10,990$580.36+$45.7KBIOC
2$304,294$243,637.85$12,301$860.26+$292.0KBIOC
3$1,547,860$1,222,266.18$14,104$1,298.62+$1.53MBIOC
4$7,466,811$5,810,600.46$16,691$2,008.16+$7.45MBIOC
5$34,185,829$26,196,340.96$20,580$3,205.09+$34.17MBIOC
6$148,669,080$112,090,243.27$26,754$5,330.02+$148.64MBIOC
7$614,649,543$455,573,627.83$37,196$9,345.14+$614.61MBIOC
8$2,417,954,821$1,760,279,809.21$56,244$17,523.09+$2417.90MBIOC
9$9,058,914,211$6,471,702,552.56$94,286$35,736.21+$9058.82MBIOC
10$32,353,185,873$22,660,147,667.77$178,949$80,797.29+$32353.01MBIOC

BIOC vs ADC: Complete Analysis 2026

BIOCStock

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

Full BIOC Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this BIOC vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BIOC vs SCHDBIOC vs JEPIBIOC vs OBIOC vs KOBIOC vs MAINBIOC vs NNNBIOC vs EPRTBIOC vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.